top stories

HHS ac­tions to re­move web con­tent were ar­bi­trary, 'poor­ly thought-through,' judge rules

3 days ago
Pharma
Law

No­var­tis' Cosen­tyx fails Phase 3 study for au­toim­mune dis­ease

3 days ago
R&D
Pharma

The Trump ad­min­is­tra­tion is pro­mot­ing wear­able health de­vices — with or with­out ev­i­dence

3 days ago
Pharma
Health Tech

Latest

Most read

Chi­na’s rise splits US biotech in­vestors: Cash in, or counter? 

4 days ago
China
In Focus

Eu­ro­pean Com­mis­sion fines Alchem, clos­es API ‘car­tel’ in­ves­ti­ga­tion 

26 minutes ago
Manufacturing
Law

Ap­ple Tree says its biotechs face ‘im­mi­nent col­lapse’; Ad­vo­cates urge J&J to pro­ceed with eye gene ther­a­py; ...

Yesterday
Weekly

Cloud­break’s shares stum­ble in Hong Kong de­but; Sino­vac squares off against ac­tivist

3 days ago
News Briefing
see latest stream
People

4DMT lays off staff, reshuf­fles team as it dou­bles down on Phase 3 plans

3 days ago

Sage plans to lay off al­most every em­ploy­ee af­ter ink­ing Su­per­nus deal

6 days ago

Trump’s CDC nom­i­nee side­steps Sen­ate grilling on con­tro­ver­sial changes

Last week
Financing

Num­ber of megarounds drops 38% in first half as biotechs strug­gle against wors­en­ing slump

3 days ago

Ex­clu­sive: VC firm lines up $200M fund to cham­pi­on Japan­ese in­no­va­tion

5 days ago

Ex­clu­sive: Sama Fer­til­i­ty rais­es $3.8M to make IVF more ac­ces­si­ble

5 days ago
Startups

Un­nat­ur­al Prod­ucts taps ar­genx's help for ringed mol­e­cules, ex­pands in­ter­nal work in­to obe­si­ty

5 days ago

Ex­clu­sive: Bob Langer-found­ed Syn­tis Bio gets $33M Se­ries A for obe­si­ty, rare dis­ease drugs

5 days ago

Ex­clu­sive: Khosla Ven­tures backs start­up sell­ing ‘ther­a­peu­tic plas­ma ex­change’ at longevi­ty clin­ics

6 days ago
Deals

Sage talked to 43 'coun­ter­par­ties' be­fore ink­ing Su­per­nus deal

3 days ago

Sh­iono­gi, BioVer­sys team up on an­tibi­otics for lung dis­ease in deal worth up to $614M

4 days ago

Kevin Tang's Con­cen­tra snags an­oth­er buy­out, this time for IGM Bio­sciences

5 days ago

In FocusSee all

Ad­vo­cates urge J&J to ‘put every­thing on the ta­ble’ for gene ther­a­py de­spite failed tri­al

5 days ago
R&D
Cell/Gene Tx

How a tai­lored ALS drug could help broad­en rare dis­ease ther­a­pies

3 weeks ago
R&D
Discovery

With HIV pre­ven­tion un­der at­tack, how might Gilead’s new PrEP in­jec­tion fare?

4 weeks ago
Pharma

Have sky-high sales pro­jec­tions set the obe­si­ty mar­ket up to fail?

4 weeks ago
Pharma

Endpoints Standouts

Will CRISPR mat­ter?

4 months ago
R&D
Special

Big am­bi­tions at Mer­ck and As­traZeneca — along with a few gi­ant pit­falls — re­shape top ranks of the R&D 15

3 months ago
Bioregnum
R&D

Il­lu­mi­na was built on DNA. Its fu­ture could be bi­ol­o­gy’s next big wave

3 months ago
In Focus
Diagnostics

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

4 months ago
Financing
Bioregnum

Peer review See all

Jul
3

Now pri­vate, blue­bird bio con­tin­ues lead­er­ship re­vamp; Roche R&D ex­ec an­nounces re­tire­ment

Jun
27

Bill Meury brings new per­spec­tive to In­cyte as Hop­penot re­tires; Ex-Mor­phoSys CEO leads re­vi­tal­ized Vor Bio

Jun
20

Roche's ven­ture arm chief to step down in 2026; As­traZeneca obe­si­ty leader has re­tired

Jun
13

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

Jun
6

GSK taps Sanofi vet to lead vac­cine R&D; Bris­tol My­ers names head of cor­po­rate af­fairs

Pharma channel feed

3 days ago

Dizal’s lung can­cer pill ap­proval sets up com­pe­ti­tion with J&J

Dizal said that its EGFR in­hibitor sun­voz­er­tinib has been ap­proved by the FDA for cer­tain types of lung can­cer.

READ MORE

FDA re­view­ers ad­vised broad la­bel for Mod­er­na’s next-gen Covid vac­cine. Prasad over­ruled them

4 days ago
FDA+

Ab­b­Vie los­es bid to block Ten­nessee's 340B con­tract phar­ma­cy law

4 days ago
Law
latest in Pharma

CDC ex­pands RSV vac­cine rec­om­men­da­tions, sid­ing with pre­vi­ous pan­el of agency ad­vi­sors

4 days ago
FDA+

Af­ter de­lay, Re­gen­eron wins US ap­proval of bis­pe­cif­ic in mul­ti­ple myelo­ma

4 days ago
FDA+

Ab­b­Vie cans oral ul­cer­a­tive col­i­tis drug from Lan­dos buy­out

4 days ago
R&D

So­ri­ot mulls mov­ing As­traZeneca stock list­ing to the US — re­port

4 days ago

Fed­er­al judge or­ders block on parts of HHS re­or­ga­ni­za­tion plan af­ter states sue

5 days ago
Law
see latest stories

Marketing channel feed

3 weeks ago

Eli Lil­ly makes all Zep­bound dos­es avail­able in sin­gle-dose vials 

Eli Lil­ly said it will make the two high­est dos­es of its pop­u­lar obe­si­ty drug Zep­bound avail­able to cer­tain pa­tients in cheap­er, sin­gle-dose vials.

READ MORE

HHS says it may re­vis­it an­ti-obe­si­ty drug poli­cies af­ter drop­ping Biden-era pro­pos­al

3 months ago
Pharma
Law

RFK Jr. has long crit­i­cized drug ads. He just slashed the FDA of­fice that reg­u­lates them

3 months ago
Pharma
FDA+
latest in Marketing

J&J touts new sur­vival da­ta pit­ting lung can­cer com­bo against As­traZeneca's ri­val

3 months ago
R&D
Pharma

No­vo Nordisk slash­es We­govy price by near­ly two-thirds for cash-pay­ing pa­tients

4 months ago
Pharma

Mis­lead­ing ex­hib­it booth pan­el lands NJ drug­mak­er an un­ti­tled let­ter from FDA

4 months ago
FDA+

Eli Lil­ly ex­pands Zep­bound sin­gle-dose vial op­tions at low­er price

4 months ago
Pharma

J&J's new can­cer com­bo beats As­traZeneca's Tagris­so on sur­vival in lung tri­al

6 months ago
Pharma
see latest stories

FDA+ channel feed

5 days ago

PBM re­forms fail to make the cut as Sen­ate pass­es Trump’s mega­bill

Ef­forts to rein in phar­ma­cy ben­e­fit man­agers, for which drug­mak­ers have been build­ing bi­par­ti­san sup­port over the years, were left out of the Sen­ate-passed ver­sion of Pres­i­dent Don­ald ...

READ MORE

CBER chief Prasad sug­gests Covid vac­cine harms may out­weigh ben­e­fits in 'low-risk pop­u­la­tion­s'

6 days ago
R&D
Pharma

FDA loosens safe­ty re­quire­ments for CAR-Ts in move to boost ac­cess

Last week
R&D
latest in FDA+

FDA head Makary’s short-lived CRL ask on KalVista’s drug rais­es more con­cerns of po­lit­i­cal in­ter­ven­tion

Last week

De­bate on a long-scru­ti­nized vac­cine in­gre­di­ent con­sumes CDC pan­el in its sec­ond day

Last week
R&D

Re­built CDC pan­el will re­assess cu­mu­la­tive vac­cine ef­fects, old­er shots

Last week
R&D

FDA in­ves­ti­gat­ing Sarep­ta’s Duchenne gene ther­a­py fol­low­ing pa­tient deaths

Last week
Cell/Gene Tx

For­mer FDA sci­en­tist and psy­che­delics re­searcher hired as CDER deputy di­rec­tor

Last week
People
see latest stories

Manufacturing channel feed

3 days ago

Tor­rent Phar­ma’s $1.38B JB Chem­i­cals takeover; Fu­ture Pak to buy Ther­at­e­ch­nolo­gies

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more.

READ MORE

Ex­clu­sive: Ger­man CD­MO BioSpring em­barks on €100M+ nu­cle­ic acid fac­to­ry

3 days ago

Hik­ma pledges $1B to ex­pand US man­u­fac­tur­ing pres­ence

6 days ago
Pharma
latest in Manufacturing

Uni­cy­cive gets a CRL for chron­ic kid­ney dis­ease pill as third-par­ty pro­duc­tion is­sues linger

6 days ago
Pharma

Bharat, GSK to cut malar­ia vac­cine price; Emer­gen­t's US stock­pile deal ex­pands

Last week

Phar­ma com­pa­nies are weigh­ing how a drug’s IP lo­ca­tion could im­pact tar­iffs

3 weeks ago
Pharma

En­zene, Ve­r­a­no­va sep­a­rate­ly un­veil ex­pan­sions; Lot­te's new ADC client

3 weeks ago

BioN­Tech stops mak­ing cell ther­a­py at Mary­land site af­ter drop­ping germ cell tu­mor in­di­ca­tion

3 weeks ago
R&D
Cell/Gene Tx
see latest stories
A service from the Financial Times